Sequencing Quadruple Therapy for Heart Failure with Reduced Ejection Fraction: Does It Really Matter?

Cardiol Clin. 2023 Nov;41(4):511-524. doi: 10.1016/j.ccl.2023.06.007.

Abstract

The conventional sequence of guideline-directed medical therapy (GDMT) initiation in heart failure with reduced ejection fraction (HFrEF) assumes that the effectiveness and tolerability of GDMT agents mirror their order of discovery, which is not true. In this review, the authors discuss flexible GDMT sequencing that should be permitted in special populations, such as patients with bradycardia, chronic kidney disease, or atrial fibrillation. Moreover, the initiation of certain GDMT medications may enable tolerance of other GDMT medications. Most importantly, the achievement of partial doses of all four pillars of GDMT is better than achievement of target dosing of only a couple.

Keywords: Beta blockers; Guideline-directed medical therapy; Heart failure with reduced ejection fraction; Mineralocorticoid receptor antagonists; Renin–angiotensin aldosterone system inhibitors; Sequence; Sodium–glucose cotransporter 2 inhibitors; Tolerability.

Publication types

  • Review

MeSH terms

  • Atrial Fibrillation
  • Drug Tolerance
  • Heart Failure* / drug therapy
  • Humans
  • Renal Insufficiency, Chronic
  • Stroke Volume